<DOC>
	<DOCNO>NCT02890745</DOCNO>
	<brief_summary>The purpose study investigate effect empagliflozin oxidative stress patient type 2 diabetes . The association examine compare difference oxidative modification 14 day treatment 25 mg empagliflozin compare placebo treatment . The study randomise , double-blinded , placebo control . Each treatment group consist 17 male type 2 diabetes . Oxidative modification measure urinary excretion 8-oxo-7,8-dihydro-2'-deoxyguanosine 8-oxo-7,8-dihydroguanosine . A student t-test perform compare drug treatment placebo . The result publish peer-review journal .</brief_summary>
	<brief_title>The Effect Effect Empagliflozin Oxidative Stress Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>Diagnosed type 2 diabetes HbA1c : 6.59.0 % Capable understanding oral write information Estimated glomerular filtration rate ( eGFR ) &lt; 60 mL/hour/1.73 m2 Currently receive insulin treatment Coronary artery bypass grafting , percutaneous coronary intervention , acute coronary syndrome , stroke , lung embolism , deep vein thrombosis , transitory cerebral ischemia within 6 month Genital infection within 14 day Plasma alanine aminotransferase â‰¥3 time upper normal limit Treatment sodium glucose cotransporter ( SGLT ) 2 inhibitor within 2 month Hyperglycaemic symptom Psychiatric disorder Intolerance empagliflozin agent relevant study Noncompliant</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Empagliflozin</keyword>
	<keyword>Oxidative stress</keyword>
	<keyword>Oxidative nucleic acid modification</keyword>
	<keyword>8-oxo-7,8-dihydro-2'-deoxyguanosine</keyword>
	<keyword>8-oxo-7,8-dihydroguanosine</keyword>
</DOC>